title: Susceptibility of penicillin-resistant and penicillin-susceptible Streptococcus pneumoniae to newer antimicrobial agents.
abstract: Agar dilution minimum inhibitory concentration (MIC) methodology, according to NCCLS guidelines, was used to test the activity of three glycopeptides (LY 333328 [LY], vancomycin [VAN], and teicoplanin [TEI]), four fluoroquinolones (trovafloxacin [TRO], BAY 12-8039 [BAY], ciprofloxacin [CIP], and ofloxacin [OFL]), five macrolide-lincosamide-streptogramin antibiotics (erythromycin [ERY], azithromycin [AZI], miocamycin [MOM], clindamycin CLN], and quinupristin-dalfopristin [SYN] against 126 Streptococcus pneumoniae strains, isolated in Lozano Blesa Hospital of Zaragoza (Spain). MIC50/MIC90 (microg/ml) values for penicillin-susceptible (PS), penicillin-intermediate (PI) and penicillin-resistant (PR) strains show an excellent antipneumococcal activity of LY 333326--a new glycopeptide, for the fluoroquinolones trovafloxacin and moxifloxacin [BAY 12-8039], and for quinupristin/dalfopristin, regardless of the resistance phenotype of the strains.
authors.affiliation: Department of Microbiology, University Hospital, Zaragoza, Spain.
authors.forename: M C
authors.initials: MC
authors.lastname: Rubio
authors.forename: P
authors.initials: P
authors.lastname: Goñi
authors.forename: Y
authors.initials: Y
authors.lastname: Vergara
authors.forename: C
authors.initials: C
authors.lastname: Seral
authors.forename: C
authors.initials: C
authors.lastname: García
authors.forename: P
authors.initials: P
authors.lastname: Gómez-Lus
authors.forename: R
authors.initials: R
authors.lastname: Gómez-Lus
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D024841:Fluoroquinolones; D006020:Glycopeptides / Q000627:therapeutic use; D018942:Macrolides; D008826:Microbial Sensitivity Tests; D010403:Penicillin Resistance; D013296:Streptococcus pneumoniae / Q000187:drug effects*
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D006020:Glycopeptides; D018942:Macrolides